01 / TITRATION
Genome titer
Measure vector genome concentration (vg/mL) by qPCR or ddPCR before and after storage or thawing. Paired measurements help quantify titer recovery and identify losses associated with each freeze-thaw cycle.
AAV Quality Resource
AAV Freeze-Thaw Stability: Effects, Best Practices, and Quality Assessment
AAV freeze-thaw stability should be judged by functional potency and particle quality—not by vg/mL titer alone. Repeated or poorly controlled freeze-thaw cycles can reduce transduction activity, increase aggregation and free DNA, and alter particle integrity even when genomic titer remains unchanged. Reliable AAV handling therefore requires single-use aliquots, controlled storage and thawing, minimized cycle counts, and post-thaw assessment of titer, potency, aggregation, and impurities.
01 What activity drops first? Transduction activity drops first, often well before the genomic titer does.
02 Does aggregation occur? Yes, especially in high-concentration or poorly buffered samples.
03 Is free DNA released? Capsid integrity can be compromised over cycles, releasing DNA.
04 Is there a fixed limit? No—tolerance varies by serotype, buffer, and concentration.
Direct Answer
Why freeze-thaw is more than a simple titer drop
The impact of freeze-thaw is not simply "one cycle, one titer loss." Serotype, concentration, buffer composition, and thaw conditions all shape the outcome, so no single metric captures the full effect.
A common observation is that genomic titer (vg/mL) stays roughly unchanged while transduction efficiency declines. Because qPCR/ddPCR measures genome copy number, not infectivity, a stable titer can mask functional loss.
The key principle: evaluate freeze-thaw damage with functional and particle-state readouts, not genomic titer alone.
Loss of Activity
Transduction efficiency declines
Some particles lose infectivity even when genomic titer is unchanged, reducing cell transduction and gene expression.
Aggregation
Particle clumping and heterogeneity
Temperature shifts can drive particle aggregation, especially in high-concentration samples, altering the effective dose.
Free DNA
Compromised capsid integrity
Repeated cycles can damage capsids, increasing free or unprotected genome even when total genome count is stable.
Reduced Reproducibility
Batch inconsistency across uses
Variation in freeze-thaw history across aliquots can mimic cell, MOI, or operator effects if not tracked.
Quality Indicators
What to measure after repeated freeze-thaw
If you suspect freeze-thaw has affected a sample, pair genomic titer with functional and particle-state readouts to judge whether it is still fit for use.
| Assay | What It Reflects | Detects |
|---|---|---|
| qPCR / ddPCR titer | Genome copy number (vg/mL) | Total vector genome; may miss functional loss |
| Functional / transduction assay | Actual biological activity | Loss of infectivity not seen by qPCR |
| Aggregation / particle size | Particle clumping | DLS, size shifts, visible precipitate |
| Free DNA | Capsid integrity | Unprotected genome release |
| Gene expression | Functional outcome | Reduced transgene expression in target cells |
Combine genomic titer with functional readouts within a broader viral vector analysis program to judge post-thaw fitness accurately.
Best Practices
How to minimize freeze-thaw damage
The simplest and most effective step is to aliquot by single-use volume up front, so no single tube is thawed and re-frozen repeatedly.
-
01
Aliquot Up Front
Divide by single-use volume after production to avoid re-freezing one large stock.
-
02
Store at -80 °C
Long-term storage at -80 °C preserves activity better than higher temperatures.
-
03
Thaw Slowly on Ice
Thaw on ice before use; avoid rapid or uneven temperature changes.
-
04
Avoid Agitation
Minimize vortexing, foaming, and repeated pipetting that stress particles.
-
05
Track Cycle Count
Record freeze-thaw history so later variability is not mistaken for cell or MOI effects.
Key Variables
What determines freeze-thaw tolerance
Freeze-thaw tolerance depends on the vector, its formulation, and the way the sample is handled. Assess these variables together and confirm acceptable performance with product-specific measurements rather than assuming a universal cycle limit.
Serotype
Capsid composition can influence how a vector responds to ice formation, concentrated solutes, and interfaces during freezing and thawing. Compare recovery and activity for the actual serotype and construct, because results from another AAV product may not transfer directly.
Concentration
Vector concentration changes the balance between particle interactions and losses to container surfaces. Both concentrated stocks and dilute working solutions need evaluation at their intended fill volume and formulation; measure titer recovery and aggregation rather than predicting stability from vg/mL alone.
Buffer & Excipients
Buffer species, pH, ionic strength, sugars, and surfactants can influence capsid integrity, genome retention, aggregation, and adsorption. Freezing may concentrate solutes and shift the local environment, so compare candidate formulations using matched freeze-thaw conditions and functional readouts.
Thaw Rate
Freezing and thawing rates affect the time a sample spends in partially frozen, concentrated phases. Use a defined procedure for the intended vial and volume, avoid partial thaw-refreeze events, and compare rates experimentally before selecting a handling instruction.
Storage Duration
Storage temperature, duration, and time outside the intended temperature range can interact with repeated thawing. Track temperature excursions and thawed hold time separately from cycle count so that any change in titer or potency can be traced to the relevant exposure.
Product-Specific Data
Set a practical cycle allowance from representative lots in the final container and formulation. Compare baseline and stressed samples for genome titer, capsid or particle state, free DNA where relevant, and transduction or expression; acceptance criteria should match the product's intended use.
Decision Framework
When to re-evaluate a frozen-thawed sample
Rather than a fixed cycle limit, judge whether a sample remains usable by its measured quality—genomic titer, activity, and particle state together.
Transduction drops but titer holds
Re-evaluate: when expression falls despite stable vg/mL, run a functional assay before drawing conclusions.
Visible precipitate or size shift
Check aggregation: DLS or size analysis can confirm whether particles have clumped.
Total genome vs. functional mismatch
Assess capsid integrity: free DNA and capsid status clarify whether genomes remain protected.
High-stakes in vivo use
Be conservative: for CNS, ocular, and other sensitive administration, prefer fresh aliquots with low freeze-thaw history.
From Question to Evidence
Creative Biolabs Support
Creative Biolabs can characterize your AAV after freeze-thaw and produce high-quality, stability-validated vector for downstream studies.
02 / ANALYSIS
Vector analysis
Characterize vector identity, genome titer, and particle state across matched pre-freeze and post-thaw samples. The combined results help distinguish a change in measurable genomes from a broader change in vector quality.
03 / POTENCY
Potency and activity
Compare transduction or expression in a relevant cell assay before and after freeze-thaw exposure. Functional results can reveal reduced activity even when the measured vector genome titer appears stable.
04 / PURITY
Purity and integrity
Assess capsid integrity, aggregation, and free DNA alongside relevant purity attributes after thawing. These measurements help identify physical changes that may affect handling, assay performance, or suitability for downstream experiments.
05 / PRODUCTION
rAAV production
Produce rAAV under a defined formulation and handling plan, then evaluate representative samples after the intended storage and thaw conditions. The resulting data support practical choices for aliquoting, shipment, and downstream use.
Selected Reading
Scientific context
Stability & Compatibility
Gruntman AM, Su L, Su Q, Gao G, Mueller C, Flotte TR. Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials. Hum Gene Ther Methods. 2015;26(2):71-76. https://doi.org/10.1089/hgtb.2015.040.
Stability Assays
Howard DB, Harvey BK. Assaying the stability and inactivation of AAV serotype 1 vectors. Hum Gene Ther Methods. 2017;28(1):39-48. https://doi.org/10.1089/hgtb.2016.180.
Production & Characterization
Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc. 2006;1(3):1412-1428. https://doi.org/10.1038/nprot.2006.207.
FAQ
AAV freeze-thaw stability questions
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
